Abstract
Study of 51 female patients showed high efficacy of alfacalcidol (Alfa D3 - Teva) and ibandronic acid (Bonviva) combination for the treatment of postmenopausal form of systemic osteoporosis. Dependence of mineral bone density (MBD) on the primary intensity of bone tissue remodeling was observed. Assumption on the necessity of bone metabolism markers assessment at ibandronate use was confirmed. The fact that use of active form of vitamin D 3 eliminates such side effects of bisphosphonates as secondary hyperparathyroidism and hypocalcemia has been proved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: N.N. Priorov Journal of Traumatology and Orthopedics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
